☆ 4.8 Article

HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis

BMC MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

HER2-low breast cancer could be associated with an increased risk of brain metastasis

Deniz Can Guven et al.

Summary: Through long-term follow-up of 2686 breast cancer patients, the study found an increased risk of brain metastasis in patients with HER2-low breast cancer. Both HER2-low and HER2-positive patients showed increased risk of brain metastasis, and HR+-HER2-low disease had poorer disease-free survival compared to HR+-HER2-negative disease.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status

Nanae Horisawa et al.

Summary: The study retrospectively reviewed data from nearly 5000 primary breast cancer patients to determine the frequency of HER2-low and compare the prognosis of HER2-low patients with HER2-negative patients. The research found that HER2-low patients did not have significantly different prognosis than HER2-0 patients. Tailoring therapies for HER2-low early breast cancer patients based on hormone receptor status may be considered.

BREAST CANCER (2022)

添加到收藏夹

Article Oncology

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer

Raz Mutai et al.

Summary: This study compared disease characteristics and outcomes between HER2-low and HER2-0 in estrogen receptor positive, early-stage breast cancer, finding significantly favorable outcomes of HER2-low expression compared to HER2-0 in women with high genomic risk.

BREAST (2021)

添加到收藏夹

Article Oncology

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Francesco Schettini et al.

Summary: Novel antibody-drug conjugates targeting HER2 have shown high activity in HER2-negative breast cancer with low HER2 expression, but the clinical and molecular characteristics of HER2-low breast cancer remain unclear. This study reveals that HER2-low is more common in HR-positive disease than in TNBC, and emphasizes the significant biological heterogeneity of HER2-low BC, highlighting the importance of reproducible and sensitive assays for measuring low HER2 expression.

NPJ BREAST CANCER (2021)

添加到收藏夹

Article Oncology

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

Sara M. Tolaney et al.

Summary: This study assessed the adherence of primary efficacy end points in adjuvant breast cancer trials to standardized definitions. Simulation modeling revealed the impact of excluding second nonbreast primary cancers on outcomes, leading to the recommendation of adding invasive breast cancer-free survival as an additional end point.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Evolution of HER2-low expression from primary to recurrent breast cancer

Federica Miglietta et al.

Summary: This study revealed that HER2-low expression is common in both primary and recurrent samples of HER2-negative breast cancer patients, and that HER2 expression is highly unstable during disease progression. Relapse biopsy from patients with primary HER2-negative tumors may present new therapeutic opportunities for a significant proportion of patients.

NPJ BREAST CANCER (2021)

添加到收藏夹

Meeting Abstract Oncology

HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting

J-S. Frenel et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer

Luciana de Moura Leite et al.

Summary: Our study does not support HER2-low as a biologically distinct subtype of breast cancer, showing no prognostic value on survival outcomes and no predictive effect for pathological complete response after conventional neoadjuvant chemotherapy.

BREAST CANCER RESEARCH AND TREATMENT (2021)

添加到收藏夹

Article Oncology

Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

Alexander Hein et al.

Summary: This study found that low HER2 expression levels in advanced breast cancer patients have limited impact on disease progression. In some patient groups, low HER2 expression appears to have no effect on prognosis.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Meeting Abstract Oncology

Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay.

Marietta Scott et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert et al.

Summary: The development of anti-HER2 antibody-drug conjugates provides new therapeutic options for breast cancer patients, including those with low expression of HER2. HER2-low-positive breast cancer is a distinct subtype with specific biology, showing differences in response to therapy and prognosis, especially in hormone receptor-negative tumors.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

Rosie Bradley et al.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis

Elisa Agostinetto et al.

Summary: The study characterized PAM50 intrinsic subtypes within HER2-low breast cancer and investigated the prognostic impact of HER2-low status on survival outcomes. The distribution of HER2-enriched tumors was higher in the HER2-low/HR- group compared to the HER2-low/HR+ group. However, there were no significant differences in survival outcomes between HER2-low subtypes and each non-HER2-low subtype when paired by HR status.

CANCERS (2021)

添加到收藏夹

Article Oncology

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry

Simon Peter Gampenrieder et al.

Summary: This study investigated the frequency of low HER2 expression and its impact on prognosis in metastatic breast cancer patients in Austria. The results showed that low HER2 expression did not have any influence on the prognosis of metastatic breast cancer in this real-world population.

BREAST CANCER RESEARCH (2021)

添加到收藏夹

Article Health Care Sciences & Services

Effects of housing value and medical subsidy on treatment and outcomes of breast cancer patients in Singapore: A retrospective cohort study

Fuh Yong Wong et al.

Summary: The study showed that breast cancer patients with lower housing values in Singapore tend to have more severe diseases, lower treatment compliance, and poorer survival rates. Enhanced medical subsidies can mitigate some socioeconomic disadvantages in improving treatment compliance but were not found to independently affect survival rates.

LANCET REGIONAL HEALTH-WESTERN PACIFIC (2021)

添加到收藏夹

Review Oncology

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Paolo Tarantino et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Medical Laboratory Technology

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Antonio C. Wolff et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)

添加到收藏夹

Article Oncology

Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer

Holm Eggemann et al.

ENDOCRINE-RELATED CANCER (2015)

添加到收藏夹

Article Medical Laboratory Technology

A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas Impact of 2007 American Society of Clinical Oncology/College of American Pathologists Criteria

Kurt A. Schalper et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)

添加到收藏夹

Article Pathology

Distinguishing Score 0 From Score 1+in HER2 Immunohistochemistry-Negative Breast Cancer Clinical and Pathobiological Relevance

Kathleen Lambein et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2013)

添加到收藏夹

Article Oncology

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Antonio C. Wolff et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Jianjiong Gao et al.

SCIENCE SIGNALING (2013)

添加到收藏夹

Article Multidisciplinary Sciences

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Christina Curtis et al.

NATURE (2012)

添加到收藏夹

Article Medicine, General & Internal

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Jose Baselga et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Oncology

Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer

Valentina Rossi et al.

ONCOLOGIST (2012)

添加到收藏夹

Editorial Material Oncology

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Ethan Cerami et al.

CANCER DISCOVERY (2012)

添加到收藏夹

Article Biotechnology & Applied Microbiology

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

Craig H. Mermel et al.

GENOME BIOLOGY (2011)

添加到收藏夹

Article Oncology

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

M. Elizabeth H. Hammond et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Oncology

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

Antonio C. Wolff et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

添加到收藏夹

Article Medicine, General & Internal

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

DJ Slamon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.